CRISPR Therapeutics

Leading gene-editing company developing CRISPR/Cas9-based therapeutics, including Casgevy (exagamglogene autotemcel), the first FDA-approved CRISPR gene therapy for sickle cell disease and beta-thalassemia.

Location
Zug, Switzerland & Boston, Massachusetts, USA
Founded
2013
Investors
1
Categories
therapeutics, biotech, gene-editing, crispr, cell-therapy, genetic-diseases

Investors

NameLocationTypeStagesPortfolio
Vertex PharmaceuticalsBoston, Massachusetts, USAcvc
series-aseries-b+2
1